Systemic application of bone-targeting peptidoglycan hydrolases as a novel treatment approach for staphylococcal bone infection

mBio. 2023 Oct 31;14(5):e0183023. doi: 10.1128/mbio.01830-23. Epub 2023 Sep 28.

Abstract

The rising prevalence of antimicrobial resistance in S. aureus has rendered treatment of staphylococcal infections increasingly difficult, making the discovery of alternative treatment options a high priority. Peptidoglycan hydrolases, a diverse group of bacteriolytic enzymes, show high promise as such alternatives due to their rapid and specific lysis of bacterial cells, independent of antibiotic resistance profiles. However, using these enzymes for the systemic treatment of local infections, such as osteomyelitis foci, needs improvement, as the therapeutic distributes throughout the whole host, resulting in low concentrations at the actual infection site. In addition, the occurrence of intracellularly persisting bacteria can lead to relapsing infections. Here, we describe an approach using tissue-targeting to increase the local concentration of therapeutic enzymes in the infected bone. The enzymes were modified with a short targeting moiety that mediated accumulation of the therapeutic in osteoblasts and additionally enables targeting of intracellularly surviving bacteria.

Keywords: MRSA; Staphylococcus aureus; antibiotic resistance; bacteriophages; cell-penetrating homing peptide; endolysin; osteomyelitis; peptidoglycan hydrolase; phage display; protein therapeutics; tissue-targeting.

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use
  • Bacteria
  • Humans
  • N-Acetylmuramoyl-L-alanine Amidase / therapeutic use
  • Peptidoglycan
  • Staphylococcal Infections* / drug therapy
  • Staphylococcal Infections* / microbiology
  • Staphylococcus aureus*

Substances

  • Peptidoglycan
  • N-Acetylmuramoyl-L-alanine Amidase
  • Anti-Bacterial Agents